News

Xantrex Partners with Germany’s Relatio MD

April 09, 2006 by Jeff Shepard

Xantrex Technology Inc. has partnered with solar sales and marketing company Relatio MD, located in Balingen, Baden-Wuerttemberg, Germany to provide commercial solar photovoltaic systems and services for project developers, engineers and installers. This alliance will focus on the distribution of Xantrex solar inverters, project design and component configuration, delivery of complete turnkey solutions and consulting services with regard to profitability, capital procurement and tax-related issues.

Over the past two years, Xantrex and Relatio have worked together successfully to expand sales of Xantrex portable power products through German retail channels. This partnership will now be further expanded to include sales of Xantrex commercial three phase solar inverters.

"Germany is the world's most significant market for solar products," says Bernd Kohlstruck, Vice President, Xantrex Technology Inc. "Most of Xantrex's commercial three-phase solar inverters for the European market are designed and manufactured in Germany. Xantrex has also established a 24-hour service network to support its local customers."

"The strategic partnership with Relatio MD will expand our sales for commercial three-phase solar inverters," said Kohlstruck. "We will be able to offer complete custom solutions for project developers, investors and on-site installers, which is a significant added value for the rapidly evolving solar market."

"We can look back on two successful years in the retail business together with Xantrex and we are glad to have gained the trust from such a successful company," says Bernd Bodmer, President of Relatio MD. "We are a company that thinks and acts holistically. Xantrex also pursues a holistic concept in Europe. It's hard to match Xantrex's wealth of experience and its highly efficient, high-quality products. The combination of these products with our consulting competencies will bring about perfect solutions with added value. We are convinced that Xantrex will gain a leading position with this approach," continues Bodmer.